Chief Executive Officer, Denteric
| Role | Organisation | Sources |
|---|---|---|
| Chief Executive Officer | Denteric | Brandon BioCatalyst, Brandon Capital |
Stories naming Sean McLoughlin. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Denteric has begun recruiting early Alzheimer's patients for a Phase I trial of its gingipain-targeting therapy GPV381, with funding from the CUREator+ Dementia program and the Medical Research Future Fund.
Melbourne biotech Denteric has won US regulatory clearance to trial GPV381, a vaccine-style therapy targeting the bacteria behind gum disease, with a Phase 2 study in the United States to follow.